National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedMcMahon BJ, Bruden D, Townsend-Bulson L
Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death.
The researchers examined the association of 11 risk factors with adverse outcomes in a population-based prospective cohort observational study of Alaska Native/American Indian persons with chronic infection. They found those infected with HCV genotype 3 to be at high risk for end-stage liver disease, hepatocellular carcinoma, and liver-related death.
AHRQ-funded; HS000046.
Citation: McMahon BJ, Bruden D, Townsend-Bulson L .
Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death.
Clin Gastroenterol Hepatol 2017 Mar;15(3):431-37.e2. doi: 10.1016/j.cgh.2016.10.012.
.
.
Keywords: Hepatitis, Cancer, Kidney Disease and Health, Risk, Mortality
Montenovo MI, Dick AA, Hansen RN
Donor hepatitis C sero-status does not impact survival in liver transplantation.
The researchers sought to assess the impact of both donor and recipient HCV status on patient and graft survival. They found that the use of HCV+ grafts in HCV+ recipients is not associated with worse outcomes. They conclude that with the increase in HCV+patients awaiting an organ, more consideration should be given to HCV+ donors.
AHRQ-funded; HS021686.
Citation: Montenovo MI, Dick AA, Hansen RN .
Donor hepatitis C sero-status does not impact survival in liver transplantation.
Ann Transplant 2015 Jan 22;20:44-50. doi: 10.12659/aot.892530..
Keywords: Hepatitis, Comparative Effectiveness, Outcomes, Mortality